Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMR 261

Next Previous
Drug Profile

IMR 261

Alternative Names: 10-nitro-oleic-acid; CXA-10; IMR-261

Latest Information Update: 27 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Complexa
  • Developer Complexa; Enliven Therapeutics
  • Class Antihypertensives; Nitro compounds; Oleic acids; Small molecules; Unsaturated fatty acids; Urologics
  • Mechanism of Action Heat-shock protein stimulants; NF-E2-related factor 2 stimulants; NF-kappa B inhibitors; Toll-like receptor 4 antagonists; Xanthine dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Focal segmental glomerulosclerosis; Pulmonary arterial hypertension
  • Preclinical Beta-thalassaemia; Sickle cell anaemia
  • No development reported Acute kidney injury; Renal failure

Most Recent Events

  • 23 Feb 2023 Imara Inc has been merged with Enliven Therapeutics to form Enliven Therapeutics
  • 09 Jun 2022 Preclinical pharmacodynamics data presented at the 27th Congress of the European Haematology Association (EHA-2022)
  • 14 Dec 2021 Imara plans clinical trial for Beta-thalassaemia and Sickle cell anaemia in 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top